PTC Therapeutics/$PTCT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About PTC Therapeutics
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
Ticker
$PTCT
Sector
Primary listing
Employees
939
Headquarters
Website
PTC Therapeutics Metrics
BasicAdvanced
$4.8B
7.86
$7.72
0.53
-
Price and volume
Market cap
$4.8B
Beta
0.53
52-week high
$62.18
52-week low
$34.57
Average daily volume
1.4M
Financial strength
Current ratio
203.806
Quick ratio
203.806
Long term debt to equity
-1,153.263
Total debt to equity
-1,153.263
Interest coverage (TTM)
4.59%
Profitability
EBITDA (TTM)
894.861
Gross margin (TTM)
68.30%
Net profit margin (TTM)
35.65%
Operating margin (TTM)
49.11%
Effective tax rate (TTM)
5.54%
Revenue per employee (TTM)
$1,880,000
Management effectiveness
Return on assets (TTM)
23.81%
Return on equity (TTM)
-106.04%
Valuation
Price to earnings (TTM)
7.857
Price to revenue (TTM)
2.672
Price to book
-23.31
Price to tangible book (TTM)
-23.31
Price to free cash flow (TTM)
6.926
Free cash flow yield (TTM)
14.44%
Free cash flow per share (TTM)
8.757
Growth
Revenue change (TTM)
96.00%
Earnings per share change (TTM)
-222.38%
3-year revenue growth (CAGR)
41.86%
10-year revenue growth (CAGR)
51.02%
3-year earnings per share growth (CAGR)
-0.48%
10-year earnings per share growth (CAGR)
7.29%
What the Analysts think about PTC Therapeutics
Analyst ratings (Buy, Hold, Sell) for PTC Therapeutics stock.
Bulls say / Bears say
Sephience received FDA approval for treating phenylketonuria, reducing blood phenylalanine levels by an average of 63%, with Jefferies projecting peak sales of $741 million by 2030 (Reuters).
Approval of Sephience broadens PTC’s commercial portfolio into metabolic disorders, diversifying revenue streams beyond its neuromuscular franchise (Reuters).
Sephience is under review in Japan and Brazil following recent European approval, positioning PTC for expanded global market penetration (Reuters).
FDA declined to approve vatiquinone for Friedreich’s ataxia, citing insufficient evidence of efficacy and necessitating additional studies before resubmission (Reuters).
SunTrust Robinson Investment Partners cut its price target for PTC Therapeutics to $75 from $78, reflecting reduced analyst confidence in the stock’s near-term performance (Reuters).
PTC’s existing top-selling Duchenne muscular dystrophy therapies face declining revenue due to patent expirations and regulatory scrutiny, underscoring pressure on its current revenue base (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2025.
PTC Therapeutics Financial Performance
Revenues and expenses
PTC Therapeutics Earnings Performance
Company profitability
PTC Therapeutics News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for PTC Therapeutics stock?
PTC Therapeutics (PTCT) has a market cap of $4.8B as of September 18, 2025.
What is the P/E ratio for PTC Therapeutics stock?
The price to earnings (P/E) ratio for PTC Therapeutics (PTCT) stock is 7.86 as of September 18, 2025.
Does PTC Therapeutics stock pay dividends?
No, PTC Therapeutics (PTCT) stock does not pay dividends to its shareholders as of September 18, 2025.
When is the next PTC Therapeutics dividend payment date?
PTC Therapeutics (PTCT) stock does not pay dividends to its shareholders.
What is the beta indicator for PTC Therapeutics?
PTC Therapeutics (PTCT) has a beta rating of 0.53. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.